Vaxcyte's total assets for Q4 2024 were $3.51B, a decrease of -1.36% from the previous quarter. PCVX total liabilities were $205.50M for the fiscal quarter, a 44.60% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.